RESUMO
BACKGROUND: A rare and benign cause of isolated aspartate aminotransferase (AST) increase is due to the presence of macro aspartate aminotransferase (macro-AST). Macro-AST is not usually considered by clinicians, leading to a large number of unnecessary and even invasive tests before diagnosed. Most commonly used laboratory methods for detection of macro-enzymes are precipitation with polyethylene glycol (PEG), ultracentrifugation and gel filtration chromatography (GFC). METHODS: We report a case of an asymptomatic patient with persistent isolated AST elevation. PEG precipitation and an alternative method based on the low stability of this macro-enzyme were performed on the patient serum. RESULTS: Macro-AST was early detected by the laboratory observing a significant decrease in AST concentrations when the serum is stored at 4ºC. CONCLUSIONS: Macro-AST detection based in this method can be very useful as screening, especially in those laboratories where other technologies are not available. Macro-AST must be considered as cause of unexplained isolated AST elevations before prior investigations to avoid the consequent cost and potential harm to the patient. In our case, early detection of macro-AST with this method avoided unnecessary treatment and invasive test such as liver biopsy.
Assuntos
Aspartato Aminotransferases/sangue , Análise Química do Sangue/métodos , Análise Química do Sangue/normas , Aspartato Aminotransferases/química , Aspartato Aminotransferases/metabolismo , Doenças Assintomáticas , Diagnóstico Diferencial , Estabilidade Enzimática , Feminino , Humanos , Pessoa de Meia-Idade , Polietilenoglicóis , TemperaturaRESUMO
No disponible
Assuntos
Humanos , Síndrome Antifosfolipídica/epidemiologia , Anticorpos Antifosfolipídeos/análise , Fatores de RiscoAssuntos
Síndrome Antifosfolipídica/epidemiologia , Aborto Habitual/epidemiologia , Adulto , Síndrome Antifosfolipídica/sangue , Síndrome Antifosfolipídica/complicações , Autoanticorpos/sangue , Comorbidade , Feminino , Humanos , Recém-Nascido , Inibidor de Coagulação do Lúpus/sangue , Lúpus Eritematoso Sistêmico/epidemiologia , Masculino , Pessoa de Meia-Idade , Trabalho de Parto Prematuro/epidemiologia , Pré-Eclâmpsia/epidemiologia , Gravidez , Complicações na Gravidez/epidemiologia , Resultado da Gravidez , Embolia Pulmonar/epidemiologia , Acidente Vascular Cerebral/epidemiologia , Trombofilia/etiologia , Trombose/epidemiologia , Adulto JovemRESUMO
BACKGROUND: The aim of the current study is to evaluate the antiplatelet effect of dexibuprofen in healthy volunteers in comparison with low-dose aspirin. METHODS: Healthy volunteers (n = 12) were treated in a crossover manner with 100 mg daily aspirin or with 800 mg daily dexibuprofen. Blood samples were obtained within 24 h; 3, 7, and 14 days after repeated doses; and 24 h after the last dose. In each sample, the authors measured platelet aggregation, thromboxane B2, 6-keto-prostaglandin F1alpha, and nitric oxide. RESULTS: The antiplatelet effect of dexibuprofen (maximal inhibition of aggregation was 48-55% for adenosine diphosphate and 90-95% for collagen and arachidonic acid) was equal to the effect of aspirin. The main difference between the two drugs was in the degree of recovery of platelet function. The effect of aspirin persisted for 24 h after the last dose (remaining inhibition 50%, respect to the pretreatment value), whereas platelet aggregation had returned to baseline pretreatment values within 24 h after dexibuprofen was stopped. CONCLUSIONS: Both aspirin and dexibuprofen inhibited platelet function with a similar intensity, but dexibuprofen exerted a reversible effect for 24 h after the last dose.
